Samsara BioCapital, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
Samsara BioCapital, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$11,878,356
+67.6%
640,6880.0%3.64%
+192.3%
Q2 2023$7,086,009
-17.6%
640,6880.0%1.24%
-30.0%
Q1 2023$8,604,440
+8.6%
640,6880.0%1.78%
+4.2%
Q4 2022$7,925,311
-11.3%
640,6880.0%1.71%
-18.1%
Q3 2022$8,938,000
+1.0%
640,6880.0%2.08%
-11.7%
Q2 2022$8,848,000
-15.1%
640,6880.0%2.36%
-10.1%
Q1 2022$10,424,000
-0.1%
640,6880.0%2.62%
+29.6%
Q4 2021$10,437,000
+9.7%
640,6880.0%2.02%
+35.6%
Q3 2021$9,514,000
-25.6%
640,6880.0%1.49%
-5.4%
Q2 2021$12,795,000
-13.5%
640,6880.0%1.58%
-42.1%
Q1 2021$14,787,000
+48.3%
640,688
+58.7%
2.73%
+171.9%
Q4 2020$9,971,000
-40.4%
403,6880.0%1.00%
-78.5%
Q3 2020$16,737,000
-13.5%
403,6880.0%4.67%
-25.0%
Q2 2020$19,341,000
-23.9%
403,6880.0%6.22%
-57.5%
Q1 2020$25,416,000
-49.2%
403,6880.0%14.63%
-39.0%
Q4 2019$50,025,000
+86.7%
403,6880.0%23.97%
+31.5%
Q3 2019$26,789,000
+1.8%
403,688
+22.1%
18.23%
+4.9%
Q2 2019$26,314,000
+11.5%
330,697
+56.8%
17.38%
-6.2%
Q1 2019$23,595,000
-0.1%
210,937
-10.0%
18.54%
-18.2%
Q4 2018$23,623,000234,37522.67%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders